Choroidal Vascularity Index in Different Cohorts of Dry Age-Related Macular Degeneration.
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
04 10 2021
04 10 2021
Historique:
entrez:
19
10
2021
pubmed:
20
10
2021
medline:
26
10
2021
Statut:
ppublish
Résumé
The purpose of this study was to investigate the choroidal luminal and interstitial stromal alterations using choroidal vascularity index (CVI) among different cohorts of dry age-related macular degeneration (dAMD) compared to healthy subjects. Four distinct cohorts were collected: three different cohorts of patients with dAMD (i.e. drusen, reticular pseudodrusen [RPD], and geographic atrophy [GA]) and an age-matched cohort of healthy subjects (controls). CVI (the ratio between the luminal choroidal area [LCA] and the total choroidal area [TCA]) was calculated in the subfoveal 1000 µm area. One hundred twenty eyes (from 120 patients) were included (30 eyes in each cohort). The mean age was 76.6 ± 7.1 years. No statistical differences were disclosed in terms of age, axial length, and central macular thickness among study groups. TCA showed a different distribution among the four cohorts (P = 0.003), mainly due to the LCA changes (P = 0.001). Interestingly, CVI showed a different distribution among the four cohorts (P < 0.001). RPD showed a lower CVI in comparison to controls (P = 0.040), whereas GA showed a lower CVI in comparison to drusen, RPD, and controls (P = 0.001, P = 0.046, and P < 0.001, respectively). Different cohorts of dAMD are characterized by different impairments of the choroidal vascular and stromal components, reflecting different degrees of AMD severity. CVI provides insights for better understanding the pathogenesis of AMD.
Identifiants
pubmed: 34665234
pii: 2778000
doi: 10.1167/tvst.10.12.26
pmc: PMC8543393
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26Références
Am J Ophthalmol. 2008 Sep;146(3):348-9
pubmed: 18724980
Ophthalmology. 2013 Apr;120(4):844-51
pubmed: 23332590
Ophthalmology. 2010 Sep;117(9):1775-81
pubmed: 20472293
Retina. 2019 Nov;39(11):2205-2211
pubmed: 30074940
Retina. 2018 Dec;38(12):2350-2355
pubmed: 29016457
Ophthalmol Retina. 2020 Feb;4(2):204-215
pubmed: 32033714
Br J Ophthalmol. 2019 Jul;103(7):911-917
pubmed: 30131381
Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4982-91
pubmed: 19357355
Ophthalmol Ther. 2017 Jun;6(1):69-77
pubmed: 28391446
Retina. 2012 Jan;32(1):25-31
pubmed: 21878837
Am J Ophthalmol. 2015 Jun;159(6):1123-1131.e1
pubmed: 25790737
Retina. 2017 Jun;37(6):1120-1125
pubmed: 27632714
Ophthalmol Retina. 2018 Nov;2(11):1097-1106
pubmed: 31047548
Retina. 2020 Apr;40(4):612-617
pubmed: 31634322
Br J Ophthalmol. 2021 Feb;105(2):222-226
pubmed: 32229515
Retina. 2020 May;40(5):960-965
pubmed: 30676528
Invest Ophthalmol Vis Sci. 2014 Jun 03;55(6):3893-9
pubmed: 24894395
Transl Vis Sci Technol. 2020 Oct 08;9(11):8
pubmed: 33133771
JAMA Ophthalmol. 2014 Mar;132(3):272-7
pubmed: 24385141
Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5201-5208
pubmed: 29049720
Exp Eye Res. 2004 Jun;78(6):1117-25
pubmed: 15109918
Br J Ophthalmol. 2018 Dec;102(12):1684-1690
pubmed: 29463502
Am J Ophthalmol. 2018 Dec;196:34-43
pubmed: 30118688
Br J Ophthalmol. 2021 Jan;105(1):97-102
pubmed: 32201374
J Clin Med. 2020 Feb 21;9(2):
pubmed: 32098215
Ophthalmol Retina. 2019 Jun;3(6):478-488
pubmed: 31174669
Am J Ophthalmol. 2017 Feb;174:42-55
pubmed: 27794427
Retina. 2014 Feb;34(2):321-9
pubmed: 23842105
Surv Ophthalmol. 1995 Mar-Apr;39(5):367-74
pubmed: 7604360
Graefes Arch Clin Exp Ophthalmol. 2020 Oct;258(10):2163-2171
pubmed: 32535671
Ophthalmology. 2013 Sep;120(9):1901-8
pubmed: 23664466
Neurobiol Aging. 2014 Nov;35(11):2562-2573
pubmed: 24925811
Clin Ophthalmol. 2017 Sep 20;11:1707-1718
pubmed: 29033536
Retina. 2018 Oct;38(10):1937-1953
pubmed: 29746415